[Treatment with statins and angiotensin-converting enzyme inhibitors in degenerative aortic stenosis--an up-date]

Area of Science:

• Cardiovascular Medicine
• Valvular Heart Disease
• Pharmacology

Context:

• Degenerative aortic stenosis (AoS) is the most common adult valvular heart disease, necessitating frequent cardiac surgeries.
• Aortic sclerosis, the primary lesion in AoS, shares risk factors and pathological features with atherosclerosis.
• The renin-angiotensin-aldosterone system is implicated in degenerative aortic disease.

Purpose:

• To review the latest literature on the definition, prevalence, and medical treatment of degenerative aortic stenosis.
• To evaluate the potential of cholesterol-lowering therapy (statins) and angiotensin-converting enzyme inhibitors in managing AoS.
• To assess the efficacy of these treatments in modifying the course of aortic sclerosis/stenosis.

Summary:

• Statins have not demonstrated effectiveness in preventing the progression of aortic valve lesions but are important for patients with concurrent coronary artery disease.
• Angiotensin-converting enzyme inhibitors do not influence the progression of aortic valve lesions but may contribute to cardiac remodeling.
• Current medical therapies show limited direct impact on the progression of degenerative aortic valve disease itself.

Impact:

• Highlights the limited role of statins and ACE inhibitors in directly treating aortic valve lesions.
• Emphasizes the importance of statins in managing associated coronary artery disease in AoS patients.
• Suggests potential benefits of ACE inhibitors in cardiac remodeling, warranting further investigation in the context of AoS.